HU193579B - Process for preparing leucine derivative and pharmaceutical composition formed therefrom - Google Patents

Process for preparing leucine derivative and pharmaceutical composition formed therefrom Download PDF

Info

Publication number
HU193579B
HU193579B HU842372A HU237284A HU193579B HU 193579 B HU193579 B HU 193579B HU 842372 A HU842372 A HU 842372A HU 237284 A HU237284 A HU 237284A HU 193579 B HU193579 B HU 193579B
Authority
HU
Hungary
Prior art keywords
lipstatin
formula
fermentation
phase
extracted
Prior art date
Application number
HU842372A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT34545A (en
Inventor
Paul Hadvary
Erich Hochuli
Ernst Kupfer
Hans Lengsfeld
Ernst K Weiber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4255488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU193579(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUT34545A publication Critical patent/HUT34545A/hu
Publication of HU193579B publication Critical patent/HU193579B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU842372A 1983-06-22 1984-06-20 Process for preparing leucine derivative and pharmaceutical composition formed therefrom HU193579B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH341583 1983-06-22

Publications (2)

Publication Number Publication Date
HUT34545A HUT34545A (en) 1985-03-28
HU193579B true HU193579B (en) 1987-10-28

Family

ID=4255488

Family Applications (1)

Application Number Title Priority Date Filing Date
HU842372A HU193579B (en) 1983-06-22 1984-06-20 Process for preparing leucine derivative and pharmaceutical composition formed therefrom

Country Status (26)

Country Link
US (1) US4598089A (cg-RX-API-DMAC7.html)
EP (1) EP0129748B1 (cg-RX-API-DMAC7.html)
JP (1) JPS6013777A (cg-RX-API-DMAC7.html)
KR (1) KR920002314B1 (cg-RX-API-DMAC7.html)
AT (1) ATE30025T1 (cg-RX-API-DMAC7.html)
AU (1) AU572851B2 (cg-RX-API-DMAC7.html)
BG (1) BG60766B2 (cg-RX-API-DMAC7.html)
CA (1) CA1247547A (cg-RX-API-DMAC7.html)
DE (2) DE19875045I2 (cg-RX-API-DMAC7.html)
DK (1) DK160496C (cg-RX-API-DMAC7.html)
ES (1) ES533557A0 (cg-RX-API-DMAC7.html)
FI (1) FI78694C (cg-RX-API-DMAC7.html)
GR (1) GR82120B (cg-RX-API-DMAC7.html)
HU (1) HU193579B (cg-RX-API-DMAC7.html)
IE (1) IE57761B1 (cg-RX-API-DMAC7.html)
IL (1) IL72122A (cg-RX-API-DMAC7.html)
LU (1) LU90302I2 (cg-RX-API-DMAC7.html)
LV (1) LV5747B4 (cg-RX-API-DMAC7.html)
MC (1) MC1602A1 (cg-RX-API-DMAC7.html)
MX (1) MX9203633A (cg-RX-API-DMAC7.html)
NL (1) NL980029I2 (cg-RX-API-DMAC7.html)
NO (2) NO159941C (cg-RX-API-DMAC7.html)
NZ (1) NZ208521A (cg-RX-API-DMAC7.html)
PH (1) PH19704A (cg-RX-API-DMAC7.html)
PT (1) PT78777B (cg-RX-API-DMAC7.html)
ZA (1) ZA844558B (cg-RX-API-DMAC7.html)

Families Citing this family (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
ZA859574B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Process for the manufacture of oxetanones
JPH0618793Y2 (ja) * 1986-06-13 1994-05-18 パイオニア株式会社 作業台
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
MY116591A (en) * 1996-04-26 2004-02-28 Hoffmann La Roche Process for the production of lipstatin and tetrahydrolipstatin
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
ES2239799T3 (es) * 1997-02-05 2005-10-01 F. Hoffmann-La Roche Ag Uso de tetrahidrolipstatina en el tratamiento de la diabetes tipo ii.
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
RU2234917C2 (ru) * 1997-12-24 2004-08-27 Кнолль Акциенгезелльшафт Терапевтические средства
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
KR20010079636A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
DE69908644T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
KR20010102964A (ko) 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물
PT1140184E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
CN1338945A (zh) 1998-12-23 2002-03-06 G·D·瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合
PL348503A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
CA2356422C (en) 1998-12-23 2008-09-16 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
DE60000796T2 (de) * 1999-01-29 2003-09-18 F. Hoffmann-La Roche Ag, Basel Reinigung von Lipstatin
WO2001005408A1 (en) * 1999-07-14 2001-01-25 Geltex Pharmaceuticals, Inc. Fat-binding polymers, optionally combined with lipase inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
HK1052183A1 (zh) 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
EP1142572A1 (de) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Oxetanon-enthaltende Präparate zur Behandlung von Darmerkrankungen
PT1296656E (pt) * 2000-06-27 2006-12-29 Hoffmann La Roche Processo para a preparação de uma composição
BR0112800A (pt) 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
AU2001289699B2 (en) * 2000-07-28 2006-06-01 Cheplapharm Arzneimittel Gmbh New pharmaceutical composition
CA2417607C (en) * 2000-08-09 2008-01-29 Christine Feinle Lipase inhibitors for the treatment of dyspepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CN1250549C (zh) 2000-12-27 2006-04-12 霍夫曼-拉罗奇有限公司 吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
CA2446324A1 (en) 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
ATE429918T1 (de) * 2001-08-30 2009-05-15 Alizyme Therapeutics Ltd Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
JP2005518347A (ja) 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
US6734314B2 (en) 2001-12-04 2004-05-11 Biogal Gyogyszergyar Rt. Preparation of orlistat and orlistat crystalline forms
WO2003048335A2 (en) 2001-12-04 2003-06-12 Biogal Gyogyszergyar Rt A fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
JP4668536B2 (ja) 2001-12-20 2011-04-13 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 膵臓リパーゼ阻害化合物、その合成および使用
JP2005521653A (ja) 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
EP1474145B1 (en) * 2002-02-04 2008-04-23 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
WO2003072577A1 (en) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Thiazole derivatives as npy receptor antagonists
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
AU2003226370A1 (en) * 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
ES2335876T3 (es) * 2002-04-26 2010-04-06 F. Hoffmann-La Roche Ag Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
MXPA05000131A (es) * 2002-07-05 2005-04-11 Hoffmann La Roche Derivados de quinazolina.
MXPA05001328A (es) * 2002-08-07 2005-04-28 Hoffmann La Roche Derivados de tiazol.
RU2296759C2 (ru) * 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
EP1567523B1 (en) * 2002-11-25 2008-08-20 F.Hoffmann-La Roche Ag Indolyl derivatives
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
RS20050890A (sr) * 2003-05-30 2007-12-31 Ranbaxy Laboratories Limited, Supstituisani pirol derivati
WO2004113314A1 (en) * 2003-06-23 2004-12-29 Biocon Limited Novel boronate esters
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2003253254A1 (en) * 2003-07-17 2005-02-04 Biocon Limited Preparation of tetrahydrolipstatin by hydrogenation of lipstatin, solvent extraction and purification
EP1656374B1 (en) * 2003-08-12 2009-03-11 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
WO2005014592A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazole npy antagonists
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2548671C (en) * 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
EP2298293A1 (en) 2004-01-16 2011-03-23 Fuji Oil Company, Limited Lipase inhibitor
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2005107777A1 (en) 2004-05-10 2005-11-17 Den Kgl. Veterinær- Og Landbohøjskole Flaxseeds for body weight management
US7879866B2 (en) * 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
EP1888585B1 (en) * 2005-05-03 2011-06-29 F. Hoffmann-La Roche AG Tetracyclic azapyrazinoindolines as 5-ht2 ligands
WO2006129826A1 (ja) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
CA2618568A1 (en) * 2005-08-18 2007-02-22 F. Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
US7355055B2 (en) * 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CA2630270A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
CN101316838B (zh) * 2005-11-30 2013-01-30 霍夫曼-拉罗奇有限公司 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物
RU2008126391A (ru) * 2005-11-30 2010-01-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 1,5-замещенного индол-2-иламида
AU2006324089A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
JP2009519290A (ja) * 2005-12-15 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー ピロロ［２，３−ｃ］ピリジン誘導体
DE602006014305D1 (de) * 2005-12-16 2010-06-24 Hoffmann La Roche Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
SK22006A3 (sk) * 2006-01-03 2007-08-02 Biotika, A. S. Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
EP1976840A1 (en) * 2006-01-13 2008-10-08 F.Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators
ATE479656T1 (de) * 2006-01-23 2010-09-15 Hoffmann La Roche Cyclohexyl-sulfonamid-derivate mit h3- rezeptoraktivität
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
KR20090015098A (ko) * 2006-05-30 2009-02-11 에프. 호프만-라 로슈 아게 피페리디닐 피리미딘 유도체
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
CN101795684A (zh) * 2007-04-09 2010-08-04 赛多斯有限责任公司 他汀类化合物与抗肥胖药的组合
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
IN2009KN04568A (cg-RX-API-DMAC7.html) 2007-06-01 2015-08-28 Univ Princeton
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
KR101504777B1 (ko) * 2007-06-06 2015-03-20 랜박시 래보러터리스 리미티드 오르리스타트의 제조 방법
EP2625968A1 (en) 2007-09-12 2013-08-14 Københavns Universitet Composition and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009039157A2 (en) * 2007-09-17 2009-03-26 Dr. Reddy's Laboratories Ltd. Orlistat pharmaceutical formulations
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
EP2280766A1 (en) 2007-12-11 2011-02-09 CytoPathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2268822B1 (en) * 2008-03-26 2019-08-28 Biocon Limited Improved fermentation process for higher yield coefficient of lipase-inhibitor with respect to consumed fatty acid
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2141236A1 (en) 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Process for production of lipstatin and microorganisms therefore
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
JP2012504600A (ja) 2008-10-03 2012-02-23 シグマ・アリメントス・ソシエダ・アノニマ・デ・カピタル・バリアブレ 総コレステロールおよびｌｄｌコレステロールの制御ならびに／または体重減少ならびに／または熱産生を促進するための組成物
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010043592A1 (en) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
RU2412713C2 (ru) * 2009-05-14 2011-02-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Фармацевтическая композиция, биологически активная добавка и способ уменьшения поглощения жира из пищи
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo PROCESS FOR PREPARING OPTICALLY PURE BETA LACTONS FROM ALDEHYDE AND COMPOSITIONS MADE THEREOF
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
US8524909B2 (en) 2010-02-02 2013-09-03 Hoffmann-La Roche Inc. Tetrahydro-pyran derivatives
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
NO2575768T3 (cg-RX-API-DMAC7.html) 2010-05-24 2018-05-12
EP2392327A1 (en) 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Use of orlistat for the anti-parasitic treatment of a parasitic disease
ES2527466T3 (es) 2010-07-06 2015-01-26 Astrazeneca Ab Agentes terapéuticos 976
CN101885713B (zh) * 2010-07-19 2011-11-30 大邦(湖南)生物制药有限公司 一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN101948450B (zh) * 2010-10-13 2013-04-24 鲁南制药集团股份有限公司 一种生产制备奥利司他的方法
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
SMT201800453T1 (it) 2010-11-04 2018-11-09 Albireo Ab Inibitori di ibat per il trattamento delle epatopatie
ES2586956T3 (es) 2010-11-08 2016-10-19 Albireo Ab Combinación farmacéutica que comprende un inhibidor de IBAT y un aglutinante de ácidos biliares
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
CN102304105B (zh) * 2011-07-15 2013-07-10 鲁南新时代生物技术有限公司 一种制备高纯度奥利司他的方法
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN103030613B (zh) * 2011-09-29 2014-11-12 北大方正集团有限公司 一种利普司他汀的提纯方法
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014060445A1 (en) 2012-10-19 2014-04-24 Akzo Nobel Chemicals International B.V. Method for preparing high purity orlistat
CN102936234B (zh) * 2012-11-15 2015-04-01 江苏阿尔法药业有限公司 一种制备脂肪酶抑制剂奥利司他的方法
CN102993134B (zh) * 2012-12-31 2015-08-05 鲁南新时代生物技术有限公司 一种利普司他汀的提纯方法
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
JP7638868B2 (ja) 2018-11-20 2025-03-04 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α－アミノ－β－カルボキシムコン酸セミアルデヒドデカルボキシラーゼ阻害剤
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
US20230338387A1 (en) 2020-02-05 2023-10-26 Nof Corporation Agent For Treating Or Preventing Pancreatic Fistula
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones

Also Published As

Publication number Publication date
BG60766B2 (bg) 1996-02-29
ES8600650A1 (es) 1985-10-16
GR82120B (cg-RX-API-DMAC7.html) 1984-12-13
FI78694B (fi) 1989-05-31
NL980029I1 (nl) 1999-01-04
US4598089A (en) 1986-07-01
MX9203633A (es) 1992-07-01
AU572851B2 (en) 1988-05-19
JPS6013777A (ja) 1985-01-24
PT78777B (en) 1986-09-15
KR920002314B1 (ko) 1992-03-21
DE3466538D1 (de) 1987-11-05
JPH0516426B2 (cg-RX-API-DMAC7.html) 1993-03-04
AU2947884A (en) 1985-01-03
NO159941C (no) 1989-02-22
MC1602A1 (fr) 1985-05-09
LV5747B4 (lv) 1996-12-20
PH19704A (en) 1986-06-16
NL980029I2 (nl) 1999-06-01
DK308584D0 (da) 1984-06-22
FI78694C (fi) 1989-09-11
IL72122A0 (en) 1984-10-31
DK160496B (da) 1991-03-18
NO2000003I1 (no) 2000-05-31
NZ208521A (en) 1988-02-29
HUT34545A (en) 1985-03-28
LV5747A4 (lv) 1996-10-20
PT78777A (en) 1984-07-01
DK308584A (da) 1984-12-23
IE841566L (en) 1984-12-22
IL72122A (en) 1987-07-31
ES533557A0 (es) 1985-10-16
EP0129748A1 (de) 1985-01-02
DK160496C (da) 1991-08-26
FI842422A0 (fi) 1984-06-14
LU90302I2 (fr) 1998-12-21
IE57761B1 (en) 1993-03-24
EP0129748B1 (de) 1987-09-30
DE19875045I2 (de) 2000-01-20
KR850000530A (ko) 1985-02-27
ATE30025T1 (de) 1987-10-15
CA1247547A (en) 1988-12-28
NO159941B (no) 1988-11-14
ZA844558B (en) 1985-02-27
NO842512L (no) 1984-12-27
FI842422L (fi) 1984-12-23

Similar Documents

Publication Publication Date Title
HU193579B (en) Process for preparing leucine derivative and pharmaceutical composition formed therefrom
WO1993016189A1 (en) Novel macrocyclic lactones and a productive strain thereof
JPH0447648B2 (cg-RX-API-DMAC7.html)
JP2768829B2 (ja) 抗生物質
JPH0366302B2 (cg-RX-API-DMAC7.html)
JP3959244B2 (ja) 生理活性化合物チロペプチンａおよびｂとその製造方法
JPH07278041A (ja) 抗腫瘍性物質ｂｅ−２４８１１及びその製造法
JP3124373B2 (ja) 免疫抑制物質
EP0233740B1 (en) Aerocavin and aerocyanidin - antibiotics
US4692310A (en) Substance K-259-2 and a process for producing the same
JPS637757B2 (cg-RX-API-DMAC7.html)
SU552907A3 (ru) Способ получени антибиотиков
JPS6311341B2 (cg-RX-API-DMAC7.html)
US5922582A (en) Indole alkaloid type compound 0089-D
BE865590A (fr) Compositions antibiotiques et leur utilisation
JPH03227971A (ja) カルバゾール化合物
JP3773310B2 (ja) Ｕｃｋ１４化合物
JPH0479354B2 (cg-RX-API-DMAC7.html)
JPH0425950B2 (cg-RX-API-DMAC7.html)
JP2000279189A (ja) 化合物の使用
JP2001055386A (ja) 抗生物質ツベラクトマイシンｂ、ｄおよびｅとその製造法
JPS6118557B2 (cg-RX-API-DMAC7.html)
JPH0372618B2 (cg-RX-API-DMAC7.html)
JPH10101676A (ja) 抗腫瘍性物質ｂｅ−５６３８４及びその製造法
JPS6326118B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
HU90 Patent valid on 900628